Research Article, J Pharm Drug Deliv Res Vol: 7 Issue: 2
Cisplatin Loaded Liposome Nanoparticles and its Efficacy on the Hepatocellular Carcinoma: An in vitro Study
Received: April 09, 2018 Accepted: June 7, 2018 Published: June 15, 2018
Citation: Ghanbari MA, Shahmabadi HE, Saffari Z, Akbarzadeh A (2018) Cisplatin Loaded Liposome Nanoparticles and its Efficacy on the Hepatocellular Carcinoma: An in vitro Study. J Pharm Drug Deliv Res 7:2. doi: 10.4172/2325-9604.1000181
Hepatocellular carcinoma (HCC)-an aggressive malignancy with high rate of mortality-is the third cause of cancer related death worldwide. Cisplatin is a chemotherapy drug used for treatment of HCC. However, serious side effects of drug limit the therapeutic dose. Nanotechnology materials such as liposome nanoparticles are capable to overcome these drawbacks and simultaneously improve the efficacy of drugs. Cisplatin encapsulated liposomal nanoparticles were successfully constructed, and after characterization, in vitro efficacy of nanodrug was evaluated. The size and zeta potential of nanoparticles were determined to be 470 nm and -20 mV. The nanoparticles showed the high retention capability in which total encapsulated drug was released after 72 h. In addition, the cytotoxicity of drug loaded nanoparticles was increased by 65% compare to the free drug on the Hepatocellular carcinoma cell line Hep G2 using MTT assay. The results of study suggested evaluating the efficacy of nanodrug on the animal model of HCC.